Article Sidebar
Published:
Jul 29, 2022DOI:
10.4314/ahs.v22i2.22Keywords:
Article Details
While African Health Sciences has been freely accessible online there have been questions on whether it is Open Access or not. We wish to clearly state that indeed African Health Sciences is Open Access. There are key issues regarding Open Access needing clarification for avoidance of doubt:
- 1. Henceforth, papers in African Health Sciences will be published under the CC BY (Creative Commons Attribution License) 4.0 International. See details on https://creativecomons.org/)
- 2. The copyright owners or the authors grant the 3rd party (perpetually and in advance) the right to disseminate, reproduce, or use the research papers in part or in full, format/medium as long as:
- No substantive errors are introduced in the process
- Attribution of authorship and correct citation details are given
- The referencing details are not changed.
Should the papers be reproduced in part, this must be clearly stated.
- 3. The papers will be freely and universally accessible online in an easily readable format such as XML in at least one widely recognized open access repository such as PUBMED CENTRAL.
B. ABRIDGED LICENCE AGREEMENT BETWEEN AUTHORS AND African Health Sciences
I submitted my manuscript to African Health Sciences and would like to affirm that:
1.0 I am authorized by my co-authors to enter into these arrangements.
2.0 I guarantee, on behalf of self and co-authors:
- That the paper is original, and has not been published in any other peer-reviewed journal; nor is it under consideration by other journal (s). It does not infringe existing copyright or any other person’s rights
- That we are/I am the sole author(s) of the paper and with authority to enter into this agreement. My granting rights to African Health Sciences is not in breach of any other obligation
- That the paper contains nothing unlawful, or libelous. Nor anything that would constitute a breach of contract, confidence or commitment given to secrecy, if published
- That I/we have taken care to ensure the integrity of the article.
3.0 I and all co-authors, agree that the paper, if accepted for publication, shall be licensed under the Creative Commons Attribution License 4.0. (see https://creativecommons.org/)
Main Article Content
Effectiveness and compliance to the use of sulphadoxine-pyrimethamine as a prophylaxis for malaria among pregnant women in Port Harcourt, Rivers State, Nigeria
Abstract
Background: Malaria during pregnancy escalates the damaging consequence to the mother and neonate. The usage of intermittent preventive treatment of malaria (IPTp) with sulfadoxine-pyrimethamine (SP) is recommended for averting the deleterious consequences of malaria in pregnancy. This study evaluated the effectiveness of, and compliance with the use of SP for malaria among pregnant women in Port Harcourt Rivers State, Nigeria.
Method: A total of 300 samples of maternal peripheral blood (MPB), 84 neonatal cord blood (NCB) and 84 placental blood (PLB) were collected from consenting mothers. Malaria parasitaemia were analysed using standard parasitological methods, and bio-data of consenting mothers were collected through questionnaires and from ANC records.
Results: Out of the samples examined for MPB, 59(19.7%) tested positive to malaria. Those with only primary education (57.1%) and women of age ≤ 20yrs (25%) had higher prevalence. Women who took SP had significantly lower prevalence (17.6%) than those that took other drugs (36.4%) (p < 0.05). Malaria prevalence was highest among women who had 3 months interval between each dose (39.1%), followed by those of 2months (23.7%) and those of 1 month (7.0%) (p < 0.05). The primigravidaes (22.8%) had an insignificantly higher prevalence than secundigravidae (19.4%) and multigravidae (15.9%). Also, 30.5% of women who registered in their third trimester of pregnancy had a significantly higher malaria parasitaemia than those who registered during their first 8.10%, or second trimesters, 19.4%. Of the 84 MPB-NCB-PLB pairedamples examined, 16.7%, 8.3% and 25% respectively were infected with malaria parasitaemia. On frequency of compliance, mothers who took SP once (37.5%) had a significantly higher MPB parasitaemia than those who took it twice (7.84%) and those of thrice (6.25%). Neonatal cord blood parasitaemia prevalence revealed that those that took SP once, that is, 25%, had a higher prevalence than others like those of twice (5.88%) and thrice (0%) respectively.
Conclusion: The use and compliance of SP reduced the prevalence of malaria among pregnant women and their new-borns.
Keywords: Compliance; Sulphadoxine-Pyrimethamine; Pregnant women; Malaria Parasitaemia.
